Caprion Teaming Up with Biomarkers Consortium to Study if Biomarkers Can Track Alzheimer’s Progression

Caprion Teaming Up with Biomarkers Consortium to Study if Biomarkers Can Track Alzheimer’s Progression
Caprion Biosciences Inc. is partnering with a public-private organization known as the Biomarkers Consortium to study whether biomarkers can be used to track changes in early Alzheimer’s disease progression. Researchers in the Cerebrospinal Fluid Proteomics Project will measure changes in protein concentration of certain biomarkers over time in Alzheimer's patients and people with mild cognitive impairment. The goal is to improve monitoring and treatment of cognitive impairment conditions. Lack of tools for determining early diagnosis and disease progression is a major challenge in the development of Alzheimer's drugs. Currently used biomarkers, such as Aß, tTau, and pTau, do not function well as markers of early diagnosis. The Biomarkers Consortium is part of the Foundation of the National Institutes of Health, a nonprofit organization that Congress authorized to help the National Institutes of Health — a government organization — carry out its mission. Organizations participating in the biomarkers project besides Caprion and the Biomarkers Consortium  include the foundation, the National Institute on Aging, the National Institute of Mental Health, the Yale School of Medicine, the University of Pennsylvania, the U.S. Food and Drug Administration, and six other companies. A previous study identified the five biomarkers that will be assessed in the project. That research measured the concentration of 142 protein biomarkers in people with Alzheimer's and mild cognit
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *